Concurrent exercise training induces additional benefits to hydrochlorothiazide: Evidence for an improvement of autonomic control and oxidative stress in a model of hypertension and postmenopause

Imagem de Miniatura
Arquivos
art_FERREIRA_Concurrent_exercise_training_induces_additional_benefits_to_hydrochlorothiazide_2023.PDF (1.47 MB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
FERREIRA, Maycon Junior
SILVA, Michel Pablo dos Santos Ferreira
BERNARDES, Nathalia
ANGELIS, Katia De
Citação
PLOS ONE, v.18, n.8, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
ObjectiveThis study aimed to evaluate whether exercise training could contribute to a better modulation of the neurohumoral mechanisms linked to the pathophysiology of arterial hypertension (AH) in postmenopausal hypertensive rats treated with hydrochlorothiazide (HCTZ). MethodsFemale spontaneously hypertensive rats (SHR) (150-200g, 90 days old) were distributed into 5 hypertensive groups (n = 7-8 rats/group): control (C), ovariectomized (O), ovariectomized treated with HCTZ (OH), ovariectomized submitted to exercise training (OT) and ovariectomized submitted to exercise training and treated with HCTZ (OTH). Ovarian hormone deprivation was performed through bilateral ovariectomy. HCTZ (30mg/kg/day) and concurrent exercise training (3d/wk) were conducted lasted 8 weeks. Arterial pressure (AP) was directly recorded. Cardiac effort was evaluated using the rate-pressure product (RPP = systolic AP x heart rate). Vasopressin V1 receptor antagonist, losartan and hexamethonium were sequentially injected to evaluate the vasopressor systems. Inflammation and oxidative stress were evaluated in cardiac tissue. ResultsIn addition to the reduction in AP, trained groups improved RPP, AP variability, bradycardic (OT: -1.3 & PLUSMN; 0.4 and OTH: -1.6 & PLUSMN; 0.3 vs. O: -0.6 & PLUSMN; 0.3 bpm/mmHg) and tachycardic responses of baroreflex sensitivity (OT: -2.4 & PLUSMN; 0.8 and OTH: -2.4 & PLUSMN; 0.8 vs. O: -1.3 & PLUSMN; 0.5 bpm/mmHg), NADPH oxidase and IL-10/TNF-& alpha; ratio. Hexamethonium injection revealed reduced sympathetic contribution on basal AP in OTH group (OTH: -49.8 & PLUSMN; 12.4 vs. O: -74.6 & PLUSMN; 18.1 mmHg). Furthermore, cardiac sympathovagal balance (LF/HF ratio), IL-10 and antioxidant enzymes were enhanced in OTH group. AP variability and baroreflex sensitivity were correlated with systolic AP, RPP, LF/HF ratio and inflammatory and oxidative stress parameters. ConclusionThe combination of HCTZ plus concurrent exercise training induced additional positive adaptations in cardiovascular autonomic control, inflammation and redox balance in ovariectomized SHR. Therefore, combining exercise and medication may represent a promising strategy for managing classic and remaining cardiovascular risks in AH.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/56414
Referências
  1. Agarwal D, 2009, HYPERTENSION, V54, P1393, DOI 10.1161/HYPERTENSIONAHA.109.135459
  2. Baker SE, 2018, HYPERTENSION, V72, P1236, DOI 10.1161/HYPERTENSIONAHA.118.11550
  3. Briones AM, 2009, HYPERTENSION, V54, P1206, DOI 10.1161/HYPERTENSIONAHA.109.136622
  4. Brito-Monzani J de O., 2021, EXP GERONTOL, V145
  5. Ceron CS, 2010, BRIT J PHARMACOL, V160, P77, DOI 10.1111/j.1476-5381.2010.00678.x
  6. CHAPLEAU MW, 1995, HYPERTENSION, V26, P341, DOI 10.1161/01.HYP.26.2.341
  7. Choudhry NK, 2022, HYPERTENSION, V79, pE1, DOI 10.1161/HYP.0000000000000203
  8. Coffey VG, 2017, J PHYSIOL-LONDON, V595, P2883, DOI 10.1113/JP272270
  9. Conti FF, 2015, AM J PHYSIOL-REG I, V309, pR1532, DOI 10.1152/ajpregu.00076.2015
  10. Corso LML, 2016, MED SCI SPORT EXER, V48, P2398, DOI 10.1249/MSS.0000000000001056
  11. da Palma RK, 2016, J APPL PHYSIOL, V121, P1032, DOI 10.1152/japplphysiol.00130.2016
  12. De Angelis K, 2005, BRAZ J MED BIOL RES, V38, P119, DOI 10.1590/S0100-879X2005000100018
  13. Done AJ, 2016, REDOX BIOL, V10, P191, DOI 10.1016/j.redox.2016.10.003
  14. Dörffel Y, 1999, HYPERTENSION, V34, P113, DOI 10.1161/01.HYP.34.1.113
  15. Eriksson JW, 2008, HYPERTENSION, V52, P1030, DOI 10.1161/HYPERTENSIONAHA.108.119404
  16. Filho AG, 2008, EXP PHYSIOL, V93, P589, DOI 10.1113/expphysiol.2007.014293
  17. Finimundi HC, 2007, J CARDIOVASC PHARM, V49, P275, DOI 10.1097/FJC.0b013e3180385ad7
  18. Ford ES, 2007, NEW ENGL J MED, V356, P2388, DOI 10.1056/NEJMsa053935
  19. Fukuzawa M, 2000, IMMUNOPHARMACOLOGY, V48, P65, DOI 10.1016/S0162-3109(00)00179-X
  20. GILES TD, 1987, AM J CARDIOL, V60, P103, DOI 10.1016/0002-9149(87)90994-5
  21. Grassi G, 2003, J HYPERTENS, V21, P1761, DOI 10.1097/00004872-200309000-00027
  22. Grégoire JP, 2002, J CLIN EPIDEMIOL, V55, P728, DOI 10.1016/S0895-4356(02)00400-6
  23. Hägg U, 2004, CLIN SCI, V107, P571
  24. Harrison DG, 2021, CIRC RES, V128, P847, DOI 10.1161/CIRCRESAHA.121.318082
  25. Irigoyen MC, 2005, HYPERTENSION, V46, P998, DOI 10.1161/01.HYP.0000176238.90688.6b
  26. Jessup JA, 2008, J AM SOC HYPERTENS, V2, P106, DOI 10.1016/j.jash.2007.10.005
  27. Kaur K, 2006, J MOL CELL CARDIOL, V41, P1023, DOI 10.1016/j.yjmcc.2006.08.005
  28. KOENIG W, 1991, J CARDIOVASC PHARM, V18, P349, DOI 10.1097/00005344-199109000-00007
  29. Köken T, 2004, CLIN BIOCHEM, V37, P50, DOI 10.1016/j.clinbiochem.2003.10.001
  30. LAKE CR, 1979, CLIN PHARMACOL THER, V26, P428, DOI 10.1002/cpt1979264428
  31. Laterza MC, 2007, HYPERTENSION, V49, P1298, DOI 10.1161/HYPERTENSIONAHA.106.085548
  32. Li JY, 2019, AM J HYPERTENS, V32, P1091, DOI 10.1093/ajh/hpz115
  33. LOWRY OH, 1951, J BIOL CHEM, V193, P265
  34. Mariappan N, 2007, AM J PHYSIOL-HEART C, V293, pH2726, DOI 10.1152/ajpheart.00376.2007
  35. MATSUKAWA T, 1991, AM J PHYSIOL, V261, pR690, DOI 10.1152/ajpregu.1991.261.3.R690
  36. Mu L, 2015, J HUM HYPERTENS, V29, P394, DOI 10.1038/jhh.2014.104
  37. Neri M, 2007, J CELL MOL MED, V11, P156, DOI 10.1111/j.1582-4934.2007.00009.x
  38. Pahlavani M, 2017, COMPR PHYSIOL, V7, P1137, DOI 10.1002/cphy.c160031
  39. Pedersen BK, 2015, SCAND J MED SCI SPOR, V25, P1, DOI 10.1111/sms.12581
  40. Peeters ACTM, 2001, EUR J CLIN INVEST, V31, P31, DOI 10.1046/j.1365-2362.2001.00743.x
  41. Pescatello LS, 2021, BMJ OPEN SPORT EXERC, V7, DOI 10.1136/bmjsem-2020-000895
  42. Pickkers P, 1999, HYPERTENSION, V33, P1043, DOI 10.1161/01.HYP.33.4.1043
  43. Qiu M, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/8244497
  44. Raheja P, 2012, HYPERTENSION, V60, P319, DOI 10.1161/HYPERTENSIONAHA.112.194787
  45. Ren CZ, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7413963
  46. Renna BF, 2006, MED SCI SPORT EXER, V38, P847, DOI 10.1249/01.mss.0000218133.89584.a6
  47. Rinder MR, 2004, AM J PHYSIOL-REG I, V287, pR360, DOI 10.1152/ajpregu.00409.2003
  48. Rodriguez-Iturbe B, 2017, PHYSIOL REV, V97, P1127, DOI 10.1152/physrev.00031.2016
  49. Roush GC, 2018, J HYPERTENS, V36, P1247, DOI 10.1097/HJH.0000000000001691
  50. Roush GC, 2014, J CARDIOVASC PHARM T, V19, P5, DOI 10.1177/1074248413497257
  51. Sanches IC, 2012, MENOPAUSE, V19, P562, DOI 10.1097/gme.0b013e3182358c9c
  52. Barroso WKS, 2021, ARQ BRAS CARDIOL, V116, P516
  53. Shi P, 2010, CLIN EXP PHARMACOL P, V37, pE52, DOI 10.1111/j.1440-1681.2009.05234.x
  54. Shimojo GL, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01471
  55. Silva GJJ, 1997, HYPERTENSION, V30, P714, DOI 10.1161/01.HYP.30.3.714
  56. Souza SBC, 2007, HYPERTENSION, V50, P786, DOI 10.1161/HYPERTENSIONAHA.107.095000
  57. Studinger P., 2003, J PHYSL, V550, P583
  58. VARDAN S, 1983, JAMA-J AM MED ASSOC, V250, P2807, DOI 10.1001/jama.250.20.2807
  59. Whelton PK, 2018, J AM COLL CARDIOL, V71, pE127, DOI 10.1016/j.jacc.2017.11.006
  60. Wray DW, 2010, HYPERTENSION, V55, P1217, DOI 10.1161/HYPERTENSIONAHA.109.147058
  61. Wu KLH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-212
  62. Xie HH, 2008, HYPERTENS RES, V31, P685, DOI 10.1291/hypres.31.685
  63. Xie HH, 2006, EUR J PHARMACOL, V543, P77, DOI 10.1016/j.ejphar.2006.05.034
  64. Yamamoto E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039162
  65. Yazdani B, 2020, J CLIN HYPERTENS, V22, P2332, DOI 10.1111/jch.14067
  66. Zaleski AL, 2019, J HYPERTENS, V37, P1877, DOI 10.1097/HJH.0000000000002115
  67. Zhou B, 2021, LANCET, V398, P957, DOI 10.1016/S0140-6736(21)01330-1

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/05
Artigos e Materiais de Revistas Científicas - LIM/59
Artigos e Materiais de Revistas Científicas - LIM/65